Business Wire

SIGFOX

19.5.2021 09:37:05 CEST | Business Wire | Press release

Share
Sabesp Delivers 92,000 Smart Water Meters Powered by the Sigfox 0G Network Operated by WND in Brazil

Sabesp, one of the largest water and sewage service providers in the world, today announces that it has successfully completed the implementation of 100,000 smart water meters with Internet of Things (IoT) technology. The project, which is one of the largest in Latin America, introduces water consumption telemeasurement in Sabesp's 100,000 largest consumers in the Metropolitan Region of São Paulo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005356/en/

The Metrolink consortium is delivering the project and comprises of companies Laager and Vita Ambiental, which won the contract after a competitive bidding process Sabesp started at the end of 2018.

WND's Sigfox 0G network was the communication technology selected by Sabesp for more than 92,000 of the total connected water meters. WND is the exclusive operator of Sigfox technology in Brazil. Sigfox technology enables the transport of data wirelessly, at low cost, over long distances, with minimum energy consumption. The devices will be in operation for at least five years without changing or recharging the battery.

Telemetering – the remote reading of meters – automates the process of measuring water consumption. The task was performed manually once a month and can now be performed multiple times a day. In addition to measurement, the system also generates alarms and important statistics about the operation of the entire water network. All of these new features bring reliability, transparency and savings to consumers and unprecedented operational efficiency for Sabesp.

Ricardo Batista, Sabesp's Division Manager and responsible for the project, comments: "The project marked the large-scale adoption of the IoT concept by Sabesp. The new technology enables our customers to monitor water consumption daily, as well as leak detection, saving money and preserving the environment, in addition to better management of resources by our company. We hope to be able to expand the project in the coming years ."

According to Felipe Duque Estrada, CEO of Laager , the success of the project is largely due to the partnership with Sigfox and WND Brazil: "The adoption of 0G network technologies from Sigfox ensured the economic and technological viability of the project. "

José Almeida, Deputy CEO of WND Brazil , adds: "Thanks to Sabesp's pioneering approach, Laager's expertise and our work together, we have delivered one of the largest IoT projects in the Americas. The results achieved demonstrate, without any doubt, that our technology and business model are the best choices for IoT projects today. "

Carlos Beato, VP Americas at Sigfox concludes: “We are incredibly proud of SABESP’s achievement and visionary take on smart water metering. The benefits of such a solution go far beyond remote reading. It truly transforms the customer experience and Quality of Service.

*****

Sabesp – Companhia de Saneamento Básico do Estado de São Paulo (http://www.sabesp.com.br/ ) is the largest sanitation company in the Americas and the fourth largest in the world in the population served. It is responsible for the supply of water, sewage collection and treatment in 375 municipalities in the State of São Paulo, besides representing 30% of the investment in basic sanitation made in Brazil.

Laager Tecnologias Sustentáveis Ltda is a company specialized in technological solutions aimed at sustainability. Its devices make it possible to control the consumption of water, gas and electricity, besides allowing greater efficiency in consumption. The company has an advanced system of individualization of these resources, which can be applied to small, medium and large consumers.

Vita Ambiental is a traditional specialized Engineering Services provider for sanitation companies, focusing on reducing losses and operational optimizations.

WND Brazil , which is part of the WND Group (https://www.wndgroup.io/ ), operates in the IoT (Internet of Things) market through the implementation of a national public network, in a B2B (Business to Business) model that allows the sale of connectivity at low cost. In just three years of operation in Brazilian territory, the company is already present in all capital cities of the country, covering an area with a population of more than 120 million inhabitants and serving more than 360 cities. WND Brazil is a pioneer in a national public network dedicated exclusively to IoT using Sigfox technology.

Sigfox is the 0G network pioneer and the world’s leading IoT (Internet of Things) service provider. Sigfox offers a unique combination of ultra-low cost and ultra-low power technologies supported by a global network, enabling businesses to gain visibility and track their assets worldwide. With more than 17 million connected devices and 70 million messages sent a day, Sigfox helps its customers to extract crucial data at the lowest cost and to accelerate their digital transformation in key areas such as Asset Tracking and Supply Chain.

ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore and Tokyo.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release

Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye